Liu Baodong
Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):266-271. doi: 10.3779/j.issn.1009-3419.2022.102.09.
Recent studies have shown that tumor immune microenvironment is closely related to tumor progression, metastasis, recurrence and response to treatment. Some immunotherapies also offer hope for cancer patients. However, the efficacy of tumor immunotherapy is uncertain and has some side effects. In order to enhance its efficacy, tumor immunotherapy combined with tumor thermal ablation has been studied. Thermal ablation has the advantages of minimally invasive, rapid recovery, safety, fewer complications, conformation, reliable effect, repeatable, low cost, and has become the fourth tumor treatment measure after surgery, radiotherapy, and drug therapy. It can directly kill tumor cells and modulate the immune system through a variety of mechanisms, although the corresponding mechanisms are not well understood, but combined tumor immunotherapy has been proposed to treat several solid malignancies. In this review, the current status and progress of thermal ablation combined with immunotherapy for lung tumor were reviewed, and further studies on the efficacy and safety of thermal ablation combined with immunotherapy were expected. .
最近的研究表明,肿瘤免疫微环境与肿瘤进展、转移、复发及治疗反应密切相关。一些免疫疗法也为癌症患者带来了希望。然而,肿瘤免疫疗法的疗效尚不确定且存在一些副作用。为了提高其疗效,人们对肿瘤免疫疗法联合肿瘤热消融进行了研究。热消融具有微创、恢复快、安全、并发症少、形态良好、效果可靠、可重复、成本低等优点,已成为继手术、放疗和药物治疗之后的第四种肿瘤治疗手段。它可以直接杀死肿瘤细胞,并通过多种机制调节免疫系统,尽管相应机制尚未完全明确,但联合肿瘤免疫疗法已被用于治疗多种实体恶性肿瘤。在这篇综述中,我们回顾了热消融联合免疫疗法治疗肺癌的现状和进展,并期望对热消融联合免疫疗法的疗效和安全性进行进一步研究。